Automated Gait Analysis in Mice with Chronic Constriction Injury
October 17th, 2017
10.4K views
The precise assessment of pain response in a neuropathic animal model is critical to investigate the pathophysiology of pain diseases and develop new analgesics. We present a sensitive and objective method to determine the sensory function of the rodent hind paw by an automated gait analysis system.
Overview
This study presents a sensitive method for assessing pain response in a neuropathic mouse model using an automated gait analysis system. It investigates the sensory function of the rodent hind paw after chronic constriction injury, aiming to address key questions in pain research.
Key Study Components
Area of Science
- Neuroscience
- Pain Research
- Behavioral Analysis
Background
- Chronic constriction injury is a common method to induce neuropathic pain in rodent models.
- Mechanical allodynia is used to evaluate pain response following peripheral nerve injury.
- Current methods may lack sensitivity in detecting subtle changes in sensory functions.
- An automated gait analysis system provides an objective assessment of locomotor function.
Purpose of Study
- To evaluate the effectiveness of an automated gait analysis system for measuring pain responses following nerve injury.
- To compare sensory function before and after surgical intervention.
- To assess the impact of analgesics, such as gabapentin, on pain responses.
Methods Used
- The study uses an automated gait analysis system to monitor rodent locomotion.
- Male ICR mice with a chronic constriction injury undergo pre- and post-surgical assessments.
- Conduct baseline measurements using the Von Frey test and automated gait analysis.
- Mice are tested daily for ten consecutive days post-surgery.
- Gait data is collected in a dark environment with specific setup parameters for the analysis system.
Main Results
- Paw withdrawal frequency increased post-surgery, indicating pain sensitivity, which could be mitigated by gabapentin treatment.
- Gait analysis revealed significant changes in hind paw print areas post-injury.
- Single stance duration was affected, highlighting the utility of the gait analysis in detecting subtle behavioral changes.
- Results indicate that both the Von Frey test and gait analysis are effective for evaluating mechanical allodynia.
Conclusions
- This procedure enables sensitive and objective analysis of neuropathic pain response in rodent models.
- The automated gait analysis system enhances the study of pain mechanisms and analgesics.
- Findings have implications for developing new treatments for pain-related diseases.
Frequently Asked Questions
What are the advantages of using an automated gait analysis system?
The automated gait analysis system offers a quick and objective way to measure various gait parameters, surpassing traditional observational methods.
How is mechanical allodynia assessed in this study?
Mechanical allodynia is assessed using the Von Frey test, where a filament is applied to the hind paw to measure withdrawal responses.
What is the significance of using the chronic constriction injury model?
The chronic constriction injury model is significant for replicating neuropathic pain conditions, allowing researchers to study pain mechanisms and treatments in a controlled manner.
What outcomes are obtained from the gait analysis?
The gait analysis provides data on various parameters, including paw print size and single stance duration, which reflect the sensory and motor function of the rodents.
How can this method be applied in future research?
This method can be applied to investigate other pain models or test various analgesic treatments, providing a reliable platform for studying pain biology.
Executive Industry Relevance
Automated gait analysis provides objective, quantitative assessment of neuropathic pain in rodent models, addressing limitations of subjective sensory tests like von Frey. This method enhances predictive confidence in target validation by delivering reproducible locomotor readouts that correlate with mechanical allodynia. It supports early discovery workflows by enabling standardized, high-throughput evaluation of analgesic efficacy in preclinical pain models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables mechanistic de-risking of analgesic targets through quantitative gait parameters such as paw print area and single stance duration.
- Operational Value: Reduces experimenter bias and variability associated with manual von Frey testing, improving data reproducibility across sites.
- Predictive Value: Supports target confidence by correlating locomotor changes with pain phenotypes in chronic constriction injury models.
Screening & Assay Development
- Scientific Value: Generates standardized, quantitative outputs (e.g., swing time, paw angle) suitable for assay optimization and hit confirmation.
- Operational Value: Automates data collection and analysis, increasing throughput and reducing manual intervention in behavioral screening.
- Assay Readiness: Establishes baseline and post-injury gait metrics that enable reliable compound evaluation in analgesic discovery programs.
Translational & Preclinical Research
- Scientific Value: Detects subtle, weight-bearing alterations in gait that reflect sensory-motor integration relevant to clinical pain assessment.
- Operational Value: Provides continuous, longitudinal monitoring of pain progression and drug response over multiple days post-injury.
- Translational Continuity: Aligns with clinical gait analysis endpoints, supporting cross-species extrapolation in analgesic development.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target hypothesis testing through lead identification to preclinical efficacy testing, particularly in neuropathic pain programs where objective functional readouts are critical.
- Discovery Biology: Supports interrogation of therapeutic hypotheses by quantifying spontaneous locomotor changes following nerve injury.
- Screening: Enables assay standardization through automated classification of compliant runs and consistent parameter extraction.
- Analytics: Delivers multivariate gait readouts (e.g., stance duration, print symmetry) that facilitate dose-response and time-course analysis.
- Translational Research: Connects preclinical locomotor deficits to clinical pain biomarkers via homologous motor-sensory pathways.
- Enterprise Reuse: Functions as a reusable platform across analgesic discovery projects due to its automated, software-driven workflow.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity in pain phenotype characterization.
- Operational Value: Enhances reproducibility and scalability through automated background subtraction and run classification.
- Strategic Value: Improves go/no-go decisions by providing objective, quantifiable biomarkers of analgesic target engagement.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on consistent, longitudinal gait metrics.
Implementation Considerations
- Requires expertise in behavioral neuroscience and video-based motion tracking systems.
- Dependent on controlled lighting, walkway calibration, and registered camera hardware for accurate footprint detection.
- Necessitates cross-team standardization of acclimation protocols and compliant run selection criteria.
- Adaptation across model systems may require adjustment of walkway length and duration thresholds.
- Practical limitations include sensitivity to environmental disturbances and exclusion of non-compliant runs, as noted in source material.
Biopharma FAQs
Why does automated gait analysis improve target validation in neuropathic pain models?
Automated gait analysis provides objective, quantitative measures of locomotor function such as paw print area and stance duration, reducing subjectivity inherent in manual tests like von Frey. This enhances reproducibility and mechanistic de-risking of analgesic targets by delivering consistent, data-driven pain phenotypes. The method supports target confidence by correlating gait changes with injury and treatment effects in chronic constriction injury models.
How does isolation of independent variables in gait analysis support the discovery pipeline?
By standardizing environmental conditions (e.g., dark testing, acclimation time) and using automated classification of compliant runs, the method isolates treatment effects from confounding variables. This enables reliable comparison of baseline versus post-injury gait parameters across experimental groups. Such control is essential for accurate lead identification and dose-response modeling in analgesic screening.
What quantitative dependent variable measurements from gait analysis enable preclinical decision-making?
The system quantifies dependent variables including hind paw print area, swing time, angle of paw, and single stance duration as percent change. These metrics allow researchers to detect significant alterations in weight-bearing and locomotion following nerve injury or drug treatment. Changes in these parameters provide objective endpoints for evaluating analgesic efficacy and target engagement.
Why do replication requirements in gait analysis matter for cross-functional collaboration?
The protocol requires at least five compliant runs per mouse to ensure reliable data acquisition, promoting consistency between operators and sites. This replication standard supports data harmonization in multi-disciplinary teams involved in discovery, screening, and preclinical development. Consistent run thresholds reduce variability and improve comparability of results across studies and departments.
What statistical analysis capabilities are required before implementing automated gait analysis in analgesic discovery?
Implementation requires the ability to perform longitudinal analysis of repeated measures (e.g., pre- and post-surgery over 10 days) and group comparisons (e.g., injury vs. sham, drug vs. vehicle). The system outputs continuous variables suitable for parametric tests such as ANOVA or t-tests to assess significance of gait changes. These capabilities are necessary to evaluate dose-response relationships and treatment effects in preclinical pain models.
